Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Phase 3CompletedNCT00047515

Alcon Research

Overview

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Alcon Investigational AgentDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.

Locations (1)

Clinical Trial Sites

Multiple Locations Throughout the United States, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.